Showing 1 - 8 results of 8 for search 'Richard B Warren', query time: 0.02s Refine Results
  1. 1
    Population Pharmacokinetic-Pharmacodynamic (popPK/PD) Relationship of Orismilast, A Potent and Selective PDE4B/D Inhibitor, in Atopic Dermatitis

    Population Pharmacokinetic-Pharmacodynamic (popPK/PD) Relationship of Orismilast, A Potent and Selective PDE4B/D Inhibitor, in Atopic Dermatitis by Richard B. Warren, Anne Weiss, Jakob Felding, Morten O. A. Sommer

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Real-World Clinical Experience of Tralokinumab in a Tertiary Centre: An Alternative for Patients with Conjunctivitis on Dupilumab?

    Real-World Clinical Experience of Tralokinumab in a Tertiary Centre: An Alternative for Patients with Conjunctivitis on Dupilumab? by Neenu Sebastian, Omar Chircop, Tim H. Clayton, Firas C. Kreeshan, Hamish J. A. Hunter, Richard B. Warren

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.

    Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of P... by Laura M Sawyer, Kinga Malottki, Celia Sabry-Grant, Najeeda Yasmeen, Emily Wright, Anne Sohrt, Emma Borg, Richard B Warren

    Published 2019-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies

    Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies by Robert Landewé, Ana-Maria Orbai, Philip J Mease, Denis Poddubnyy, Lianne S Gensler, Vishvesh Shende, Richard B Warren, Luke Peterson, Alexander Marten, Ute Massow, Katy White, Barbara Ink, Rajan Bajracharya, Myriam Manente

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study

    Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Stud... by Richard B. Warren, Lev Pavlovsky, Antonio Costanzo, Michael Bukhalo, Neil J. Korman, Yu-Huei Huang, Georgios Kokolakis, Andreas Pinter, Nadia Ibrahim, Yanbing Zheng, Leonidas Drogaris, Vassilis Stakias, Ahmed M. Soliman, Simone Rubant, Diamant Thaçi

    Published 2024-11-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study

    Correction: Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm... by Richard B. Warren, Lev Pavlovsky, Antonio Costanzo, Michael Bukhalo, Neil J. Korman, Yu-Huei Huang, Georgios Kokolakis, Andreas Pinter, Nadia Ibrahim, Yanbing Zheng, Leonidas Drogaris, Vassilis Stakias, Ahmed M. Soliman, Simone Rubant, Diamant Thaçi

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials

    Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials by Neil J. Korman, Richard B. Warren, Jerry Bagel, April W. Armstrong, Melinda Gooderham, Bruce Strober, Diamant Thaçi, Akimichi Morita, Shinichi Imafuku, Peter Foley, Howard Sofen, Min Zheng, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Andrew Blauvelt

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

    Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III... by Robert Landewé, Joseph F Merola, Laure Gossec, Frank Behrens, Ana-Maria Orbai, Philip J Mease, Iain B McInnes, Yoshiya Tanaka, Dafna D Gladman, Laura C Coates, Alice B Gottlieb, Vishvesh Shende, Jason Coarse, Christopher T Ritchlin, Richard B Warren, Akihiko Asahina, Barbara Ink, Rajan Bajracharya

    Published 2024-02-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: